GlassScriptPhysician profile
Zoltan T Erdos
NPI 1417938283
$4,768.98
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $1,145 · 2021: $1,340 · 2022: $1,099 · 2023: $119 · 2024: $27.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $719.48 | 2019-2022 | |
| Abbvie INC. | $525.45 | 2020-2023 | |
| Pfizer INC. | $403.19 | 2019-2024 | |
| Lilly USA, LLC | $333.36 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $318.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $305.01 | 2019-2023 | Shingrix, Arexvy |
| Amgen INC. | $255.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $214.54 | 2019-2022 | |
| Astellas Pharma US INC | $135.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.12 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $97.79 | 2019-2022 | |
| Allergan, INC. | $88.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $84.05 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $84.00 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoltan Erdos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.